EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Isozyme‐Specific Inhibition of GSK‐3 Reveals Distinct Cellular Responses in Huntington's Disease Fibroblasts

Yarine Lugassy, Eva Berent, Sandra Jeries, Tamar Ziv, Hagit Eldar‐Finkelman

Journal of Neurochemistry · 2026-11 · 170 (11)

DOI: 10.1111/jnc.70588 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Inhibition of glycogen synthase kinase‐3 (GSK‐3) has been implicated in alleviating Huntington's disease (HD)‐associated phenotypes. However, the mechanisms linking GSK‐3 to HD pathogenesis, and particularly the distinct roles of GSK‐3 isozymes in regulating HD‐associated cellular dysfunction, remain poorly understood. Here, we investigated the cellular responses of patient‐derived HD fibroblasts to selective inhibition of GSK‐3α or GSK‐3β using isozyme‐specific inhibitors, focusing on metabolic and bioenergetic pathways. Although inhibition of either isozyme suppressed mTORC1 signaling, selective GSK‐3β inhibition elicited broader cellular responses, including altered oxidative stress signaling, increased expression of proteins associated with mitochondrial fission, enhanced lysosomal activity, and mitophagy, together with lysosomal redistribution and increased α‐tubulin acetylation, suggesting improved microtubule‐dependent intracellular trafficking. Quantitative proteomic analysis of four independent patient‐derived HD fibroblasts corroborated these findings: GSK‐3β inhibition elicited a broad set of proteins involved in cytoskeletal organization, adhesion signaling, and metabolic adaptation, whereas GSK‐3α inhibition produced a more restricted and heterogeneous response. Collectively, these findings identify distinct cellular responses to selective GSK‐3 isozyme inhibition and reveal GSK‐3β as a predominant regulator of intracellular trafficking and mitochondrial and cytoskeletal dynamics in HD fibroblasts. Thus, inhibition of GSK‐3β may represent a potential therapeutic approach for modulating HD‐associated cellular dysfunction. image

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →